Matches in UGent Biblio for { <https://biblio.ugent.be/publication/4328980#aggregation> ?p ?o. }
Showing items 1 to 47 of
47
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B831762.
- aggregation creator B831763.
- aggregation creator B831764.
- aggregation creator B831765.
- aggregation creator B831766.
- aggregation creator B831767.
- aggregation creator B831768.
- aggregation creator B831769.
- aggregation creator B831770.
- aggregation creator B831771.
- aggregation creator B831772.
- aggregation creator B831773.
- aggregation creator B831774.
- aggregation creator B831775.
- aggregation creator B831776.
- aggregation creator person.
- aggregation date "2014".
- aggregation format "application/pdf".
- aggregation hasFormat 4328980.bibtex.
- aggregation hasFormat 4328980.csv.
- aggregation hasFormat 4328980.dc.
- aggregation hasFormat 4328980.didl.
- aggregation hasFormat 4328980.doc.
- aggregation hasFormat 4328980.json.
- aggregation hasFormat 4328980.mets.
- aggregation hasFormat 4328980.mods.
- aggregation hasFormat 4328980.rdf.
- aggregation hasFormat 4328980.ris.
- aggregation hasFormat 4328980.txt.
- aggregation hasFormat 4328980.xls.
- aggregation hasFormat 4328980.yaml.
- aggregation isPartOf urn:issn:0887-6924.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Biology and Life Sciences".
- aggregation title "JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma".
- aggregation abstract "Extranodal, nasal-type natural killer (NK)/T-cell lymphoma (NKCL) is an aggressive malignancy with poor prognosis in which, usually, signal transducer and activator of transcription 3 (STAT3) is constitutively activated and oncogenic. Here, we demonstrate that STAT3 activation mostly results from constitutive Janus kinase (JAK) 3 phosphorylation on tyrosine 980, as observed in three of the four tested NKCL cell lines and in 20 of the 23 NKCL tumor samples under study. In one of the cell lines and in 4 of 19 (21%) NKCL primary tumor samples, constitutive JAK3 activation was related to an acquired mutation (A573V or V722I) in the JAK3 pseudokinase domain. We then show that constitutive activation of the JAK3/STAT3 pathway has a major role in NKCL cell growth and survival and in the invasive phenotype. Indeed, NKCL cell growth was slowed down in vitro by targeting JAK3 with chemical inhibitors or small-interfering RNAs. In a human NKCL xenograft mouse model, tumor growth was significantly delayed by the JAK3 inhibitor CP-690550. Altogether, the constitutive activation of JAK3, which can result from JAK3-activating mutations, is a frequent feature of NKCL that deserves to be tested as a therapeutic target.".
- aggregation authorList BK1205428.
- aggregation endPage "348".
- aggregation issue "2".
- aggregation startPage "338".
- aggregation volume "28".
- aggregation aggregates 4329005.
- aggregation isDescribedBy 4328980.
- aggregation similarTo leu.2013.157.
- aggregation similarTo LU-4328980.